# BridgeBio Pharma, Inc.: Form 8-K, filed Mar 17, 2025

- Company: [BridgeBio Pharma, Inc.](/companies/bbio.md) (CIK 1743881)
- Form: 8-K
- Filed: 2025-03-17
- Accepted by EDGAR: Mar 17, 2025, 16:32 ET
- Period: 2025-03-17
- Accession: 0001140361-25-009063
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1743881/000114036125009063/ef20045625_8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1743881/000114036125009063/

## Items reported

- Item 5.02: Departure or appointment of officers or directors
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1743881/000114036125009063/ef20045625_8k.htm

Filed Mar 17, 2025.
Source: SEC EDGAR, the filing index for accession 0001140361-25-009063. Last ingested by Listed: Nov 3, 2026, 19:31 ET. No prices; not investment advice.